Drug Trial Radar · NCT00678327
Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma
Last checked: Nov 20, 2026Latest source record: May 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,202
Actual
Start
Aug 29, 2008
Primary completion
Jan 31, 2016
Study completion May 1, 2024
Sponsor
- Lead sponsor
- University College, LondonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cancer Research UK; Cancer Research UK & UCL Cancer Trials Centre
- First posted
- May 15, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Imaging procedures, such as fludeoxyglucose F 18 (FDG)-PET/CT scan, done before, during, and after chemotherapy may help doctors assess a patient's response to treatment and help plan the best treatment. It is not yet known whether FDG-PET/CT imaging is effective in assessing response to chemotherapy in patients with newly diagnosed Hodgkin lymphoma. PURPOSE: This randomized phase III trial is studying FDG-PET/CT imaging to see how well it works in assessing response to chemotherapy in patients with newly diagnosed stage II, stage III, or stage IV Hodgkin lymphoma.
Conditions
- Lymphoma
Interventions
bleomycin sulfateBiological
Given IV
filgrastimBiological
Given subcutaneously
pegfilgrastimBiological
Given subcutaneously
cyclophosphamideDrug
Given IV
dacarbazineDrug
Given IV
doxorubicin hydrochlorideDrug
Given IV
etoposideDrug
Given IV
prednisoloneDrug
Given orally
procarbazine hydrochlorideDrug
Given orally
vinblastine sulfateDrug
Given IV
vincristine sulfateDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- 3-year progression-free survivalTime frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Southampton General Hospital
Southampton, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.